icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of Glecaprevir / Pibrentasvir in Patients Infected with HCV GT1 - 3 by Renal Impairment Status: A Pooled Analysis of Two Phase 3 Japanese Trials
 
 
  Reported by Jules Levin
AASLD - the Liver Meeting 2017, 20 - 24 October 2017, Washington, DC
 
Masanori Atsukawa1, Kazuaki Chayama2, Fumitaka Suzuki3, Ken Sato4, Yoshiyasu Karino5, Tomofumi Atarashi6, Yoshiiku Kawakami2, Atsushi Naganuma7, David Pugatch8, Katia Alves8, Koji Kato8, Rebecca Redman8, Margaret Burroughs8, Manal Abunimeh8, Wangang Xie8, Hiromitsu Kumada31Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; 2Hiroshima University Hospital, Hiroshima, Japan; 3Toranomon Hospital, Tokyo, Japan; 4Gunma University Hospital, Maebashi, Japan; 5JA Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital, Sapporo, Japan; 6JA Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan; 7NHO Takasaki General Medical Center, Takasaki, Japan; 8AbbVie, Inc., North Chicago, IL

1127171

1127172

1127173

1127174

1127175

1127176

1127177